State of the art and emerging drug therapies for female infertility

References

• Practice Committee of American Society for Reproductive M. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2012;98:302–307.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London: National Institute for Health and Clinical Excellence: Guidance; 2013.
   Google Scholar
• Mazzilli R, Cimadomo D, Vaiarelli A. Effect of the male factor on the clinical outcome of intracytoplasmic sperm injection combined with preimplantation aneuploidy testing: observational longitudinal cohort study of 1,219 consecutive cycles. Fertil Steril. 2017;108:961–972.
   PubMed Web of Science ®Google Scholar
• Franasiak JM, Forman EJ, Hong KH, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2014;101:656–663.
   PubMed Web of Science ®Google Scholar
• Capalbo A, Hoffmann ER, Cimadomo D, et al. Human female meiosis revised: new insights into the mechanisms of chromosome segregation and aneuploidies from advanced genomics and time-lapse imaging. Hum Reprod Update. 2017;30:1–17.
   Google Scholar
• Heffner LJ. Advanced maternal age—how old is too old? N Engl J Med. 2004;351:1927–1929.
   PubMed Web of Science ®Google Scholar
• Vaiarelli A, Cimadomo D, Capalbo A, et al. Pre-implantation genetic testing in ART: who will benefit and what is the evidence? J Assist Reprod Genet. 2016;33:1273–1278.
   PubMed Web of Science ®Google Scholar
• Venturella R, Vaiarelli A, Lico D, et al. A modern approach to the management of candidates for assisted reproductive technology procedures. Minerva Ginecol. 2018;70:69–83.
   PubMed Web of Science ®Google Scholar
• Venturella R, Lico D, Sarica A, et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. J Ovarian Res. 2015;8:8–21.
   PubMed Web of Science ®Google Scholar
• Christou F, Pitteloud N, Gomez F. The induction of ovulation by pulsatile administration of GnRH: an appropriate method in hypothalamic amenorrhea. Gynecol Endocrinol. 2017;33:598–601.
   PubMed Web of Science ®Google Scholar
• Zeydabadi Nejad S, Ramezani Tehrani F, Zadeh-Vakili A. The role of Kisspeptin in female reproduction. Int J Endocrinol Metab. 2017;15:e44337.
   PubMed Web of Science ®Google Scholar
• Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:1413–1439.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317:516–524.
   PubMed Web of Science ®Google Scholar
• Rocca ML, Venturella R, Mocciaro R, et al. Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother. 2015;16:1369–1393.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Teede HJ, Noakes M, et al. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36:1004–1010.
   PubMed Web of Science ®Google Scholar
• Luke B. Adverse effects of female obesity and interaction with race on reproductive potential. Fertil Steril. 2017;107:868–877.
   PubMed Web of Science ®Google Scholar
• Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: what's new? Adv Clin Exp Med. 2017;26:359–367.
   PubMed Web of Science ®Google Scholar
• Usadi RS, Merriam KS. On-label and off-label drug use in the treatment of female infertility. Fertil Steril. 2015;103:583–594.
   PubMed Web of Science ®Google Scholar
• Calogero AE, Gullo G, La Vignera S, et al. Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study. Andrology. 2015;3:491–495.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Bizzarri M. Inositols in insulin signaling and glucose metabolism. Int J Endocrinol. 2018;2018:1968450.
   PubMed Web of Science ®Google Scholar
• Sortino MA, Salomone S, Carruba MO, et al. Polycystic ovary syndrome: insights into the therapeutic approach with inositols. Front Pharmacol. 2017;8:341.
   PubMed Web of Science ®Google Scholar
• Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22:687–708.
   PubMed Web of Science ®Google Scholar
• Sokalska A, Piotrowski PC, Rzepczynska IJ, et al. Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab. 2010;95:5390–5394.
   PubMed Web of Science ®Google Scholar
• Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res. 2013;40:51–63.
   PubMed Web of Science ®Google Scholar
• Talmor A, Dunphy B. Female obesity and infertility. Best Pract Res Clin Obstet Gynaecol. 2015;29:498–506.
   PubMed Web of Science ®Google Scholar
• Nazarpour S, Ramezani Tehrani F, Simbar M, et al. Effects of levothyroxine on pregnant women with subclinical hypothyroidism, negative for thyroid peroxidase antibodies. J Clin Endocrinol Metab. 2018;103:926–935.
   PubMed Web of Science ®Google Scholar
• Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27:315–389.
   PubMed Web of Science ®Google Scholar
• Garruti G, De Palo R, De Angelisc M. Weighing the impact of diet and lifestyle on female reproductive function. Curr Med Chem. 2017;24:1–9.
   Google Scholar
• Palmery M, Saraceno A, Vaiarelli A, et al. Oral contraceptives and changes in nutritional requirements. Eur Rev Med Pharmacol Sci. 2013;17:1804–1813.
   PubMed Web of Science ®Google Scholar
• van de Vijver A, Drakopoulos P, Van Landuyt L, et al. Vitamin D deficiency and pregnancy rates following frozen-thawed embryo transfer: a prospective cohort study. Hum Reprod. 2016;31:1749–1754.
   PubMed Web of Science ®Google Scholar
• Polyzos NP, Anckaert E, Guzman L, et al. Vitamin D deficiency and pregnancy rates in women undergoing single embryo, blastocyst stage, transfer (SET) for IVF/ICSI. Hum Reprod. 2014;29:2032–2040.
   PubMed Web of Science ®Google Scholar
• Zhao J, Huang X, Xu B, et al. Whether vitamin D was associated with clinical outcome after IVF/ICSI: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2018;16:13.
   PubMed Web of Science ®Google Scholar
• Daniilidis A, Balaouras D, Chitzios D, et al. Hydrosalpinx: tubal surgery or in vitro fertilisation? An everlasting dilemma nowadays: a narrative review. J Obstet Gynaecol. 2017;37:550–556.
   PubMedGoogle Scholar
• Camus E, Poncelet C, Goffinet F, et al. Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. Hum Reprod. 1999;14:1243–1249.
   PubMed Web of Science ®Google Scholar
• Venturella R, Lico D, Borelli M, et al. 3 to 5 years later: long-term effects of prophylactic bilateral salpingectomy on ovarian function. J Minim Invasive Gynecol. 2017;24:145–150.
   PubMed Web of Science ®Google Scholar
• Venturella R, Zullo F, Zupi E, et al. Effect of salpingectomy on ovarian response to hyperstimulation during in vitro fertilization: does it really matter? Gynecol Endocrinol. 2018;34:270–271.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Guo Y, et al. Salpingectomy and proximal tubal occlusion for hydrosalpinx prior to in vitro fertilization: a meta-analysis of randomized controlled trials. Obstet Gynecol Surv. 2015;70:33–38.
   PubMed Web of Science ®Google Scholar
• Noventa M, Gizzo S, Saccardi C, et al. Salpingectomy before assisted reproductive technologies: a systematic literature review. J Ovarian Res. 2016;9:74.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Buggio L, Frattaruolo MP, et al. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68–91.
   PubMed Web of Science ®Google Scholar
• Tao X, Chen L, Ge S, et al. Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: a meta-analysis. PLoS One. 2017;12:e0177426.
   PubMed Web of Science ®Google Scholar
• Endometriosis Treatment Italian Club. Ovarian endometrioma: what the patient needs. J Minim Invasive Gynecol. 2014;21:505–516.
   PubMed Web of Science ®Google Scholar
• Alabiso G, Alio L, Arena S, et al. How to manage bowel endometriosis: the ETIC approach. J Minim Invasive Gynecol. 2015;22:517–529.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420.
   PubMed Web of Science ®Google Scholar
• Venturella R, Rocca ML, Lico D, et al. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy: randomized controlled trial. Fertil Steril. 2016;105:1369–1376.
   PubMed Web of Science ®Google Scholar
• Venturella R, Miele G, Cefalì K, et al. Subcutaneous progesterone for endometrial polyps in premenopausal women: a preliminary retrospective analysis. J Minim Invasive Gynecol. 2019;26:143–147.
   PubMed Web of Science ®Google Scholar
• Morelli M, Di Cello A, Venturella R, et al. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecol Endocrinol. 2013;29:156–159.
   PubMed Web of Science ®Google Scholar
• Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol. 2010;8:112.
   PubMed Web of Science ®Google Scholar
• Santi D, Casarini L, Alviggi C, et al. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the "personalized" medicine era: a meta-analysis. Front Endocrinol (Lausanne). 2017;8:114.
   PubMed Web of Science ®Google Scholar
• Ye H, Huang G, Pei L, et al. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial. Gynecol Endocrinol. 2012;28:540–544.
   PubMed Web of Science ®Google Scholar
• Parsanezhad ME, Jahromi BN, Rezaee S, et al. The effect of four different gonadotropin protocols on oocyte and embryo quality and pregnancy outcomes in IVF/ICSI cycles: a randomized controlled trial. Iran J Med Sci. 2017;42:57–65.
   PubMed Web of Science ®Google Scholar
• Harlin J, Csemiczky G, Wramsby H, et al. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum Reprod. 2000;15:239–244.
   PubMed Web of Science ®Google Scholar
• Olsson H, Sandstrom R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014;54:1299–1307.
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387–396.e4.
   PubMed Web of Science ®Google Scholar
• Devroey P, Boostanfar R, Koper NP, et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24:3063–3072.
   PubMed Web of Science ®Google Scholar
• Corifollitropin alfa Ensure Study G. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21:66–76.
   PubMed Web of Science ®Google Scholar
• Boostanfar R, Shapiro B, Levy M, et al. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril. 2015;104:94–103.
   PubMed Web of Science ®Google Scholar
• Polyzos NP, De Vos M, Corona R, et al. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod. 2013;28:1254–1260.
   PubMed Web of Science ®Google Scholar
• Drakopoulos P, Vuong TNL, Ho NAV, et al. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Hum Reprod. 2017;32:2225–2233.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Boostanfar R, Gordon K, et al. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. Reprod Biomed Online. 2016;33:56–60.
   PubMed Web of Science ®Google Scholar
• Alviggi C, Conforti A, Esteves SC, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018;109:644–664.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;11:5.
   Web of Science ®Google Scholar
• Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Human Reprod. 2013;28:2511–2521.
   PubMed Web of Science ®Google Scholar
• Tannus S, Turki R, Cohen Y, et al. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years. Fertil Steril. 2017;107:1323–1328.
   PubMed Web of Science ®Google Scholar
• Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;31:10.
   PubMed Web of Science ®Google Scholar
• Borges E, Braga DP, Setti AS, et al. Strategies for the management of OHSS: results from freezing-all cycles. JBRA Assist Reprod. 2016;20:8–12.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online. 2014;29:274–280.
   PubMed Web of Science ®Google Scholar
• Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003;80:116–122.
   PubMed Web of Science ®Google Scholar
• Ubaldi FM, Capalbo A, Vaiarelli A, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105:1488–1495.
   PubMed Web of Science ®Google Scholar
• Vaiarelli A, Venturella R, Vizziello D, et al. Dual ovarian stimulation and random start in assisted reproductive technologies: from ovarian biology to clinical application. Curr Opin Obstet Gynecol. 2017;29:153–159.
   PubMed Web of Science ®Google Scholar
• Cimadomo D, Vaiarelli A, Colamaria S, et al. Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle. Hum Reprod. 2018. doi: 10.1093/humrep/dey217.
   Web of Science ®Google Scholar
• Vaiarelli A, Cimadomo D, Trabucco E, et al. Double stimulation in the same ovarian cycle (DuoStim) to maximize the number of oocytes retrieved from poor prognosis patients: a multicenter experience and SWOT analysis. Front Endocrinol (Lausanne). 2018;9:317.
   PubMed Web of Science ®Google Scholar
• Massin NN. stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23:211–220.
   PubMed Web of Science ®Google Scholar
• Fabris AM, Cruz M, Legidos V, et al. Dual triggering with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin in patients with a high immature oocyte rate. Reprod Sci. 2017;24:1221–1225.
   PubMed Web of Science ®Google Scholar
• O'Neill KE, Senapati S, Maina I, et al. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. J Assist Reprod Genet. 2016;33:1175–1184.
   PubMed Web of Science ®Google Scholar
• Yanushpolsky EH. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015;33:118–127.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011;5:CD009154.
   Google Scholar
• Lockwood G, Griesinger G, Cometti B, et al. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertil Steril. 2014;101:112–119.e3.
   PubMed Web of Science ®Google Scholar
• Baker VL, Jones CA, Doody K, et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Hum Reprod. 2014;29:2212–2220.
   PubMed Web of Science ®Google Scholar
• Venturella R, Vaiarelli A, Buffo L, et al. Progesterone for preparation of the endometrium for frozen-thawed blastocyst transfer in vitro fertilization cycles: a prospective study on patients' opinions on a new subcutaneous formulation. Gynecol Endocrinol. 2018;16:1–6.
   Google Scholar